Hot Features
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) acro... Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.25 | -8.47457627119 | 2.95 | 3.15 | 2.7 | 19524 | 2.87504722 | CS |
| 4 | -0.3 | -10 | 3 | 3.45 | 2.62 | 17096 | 2.94141532 | CS |
| 12 | -2.21 | -45.0101832994 | 4.91 | 5.0661 | 2.62 | 16602 | 3.56282952 | CS |
| 26 | -3.015 | -52.7559055118 | 5.715 | 6.645 | 2.62 | 32111 | 4.91503474 | CS |
| 52 | -6.69 | -71.2460063898 | 9.39 | 9.746497 | 2.62 | 208387 | 6.65129632 | CS |
| 156 | 1.73 | 178.350515464 | 0.97 | 36 | 0.2914 | 503716 | 3.53204618 | CS |
| 260 | 1.03 | 61.6766467066 | 1.67 | 36 | 0.0846 | 1816825 | 0.88202745 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.